A long-term, follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals’ novel HPV vaccine in healthy female subjects vaccinated in the primary study
Human Papillomavirus Types 16 and 18 Vaccine
Infections, Papillomavirus
Phase 2
The results of this study 108052 are summarised with studies 102115 and 107919 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.
March 2014